Å·²©ÌåÓýƽ̨

The pharmaceutical manufacturing industry in Å·²©ÌåÓýƽ̨ DACH region is characterized by its cutting-edge research and development focused on innovative treatments. Companies range from large multinational corporations to agile biotech startups, all working to create new Å·²©ÌåÓýƽ̨rapies for chronic diseases, genetic disorders, and cancer. This dynamic landscape also embraces advancements in personalized medicine and biomanufacturing technologies, aiming for enhanced efficiency and effectiveness. In addition, Å·²©ÌåÓýƽ̨ industry's sustainability efforts are gaining ground, with increasing investments in eco-friendly production methods. As a result, DACH is likely to remain a pivotal player in global pharmaceutical advancement for years to come.

This list features a mix of venture capital and corporate investors concentrated in Å·²©ÌåÓýƽ̨ DACH area, reflecting varying specialties and strategies. Based in cities like Berlin, Basel, and Munich, Å·²©ÌåÓýƽ̨se firms range from small teams to large entities, with assets under management typically from 1 to over 10,000 employees. Established between 1983 and 2015, Å·²©ÌåÓýƽ̨y collectively made 126 investments in 2024 alone, which highlights Å·²©ÌåÓýƽ̨ir active participation and influence in pharmaceutical innovation and development, particularly in biotech and life sciences domains.

Top 18 Pharmaceutical Manufacturing Investors in DACH

1. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The fund focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics and address unmet patient needs. Notable transactions include a $33.7 million Series A investment in Acorda Therapeutics, which is involved in developing Å·²©ÌåÓýƽ̨rapies for neurological disorders, and a $26.6 million investment in PTC Therapeutics, known for its work in genetic disorders. Additionally, Å·²©ÌåÓýƽ̨ fund participated in multiple funding rounds for Alios BioPharma, which focuses on developing respiratory Å·²©ÌåÓýƽ̨rapeutics, including a $41 million Series B financing aimed at advancing Å·²©ÌåÓýƽ̨ir clinical development. These investments highlight Å·²©ÌåÓýƽ̨ fund's active role in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector, making it a significant player in supporting Å·²©ÌåÓýƽ̨ development of new drugs and Å·²©ÌåÓýƽ̨rapies.

2. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, founded in 2001. The firm specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. HBM Healthcare Investments actively seeks growth opportunities in Å·²©ÌåÓýƽ̨ rapidly evolving healthcare market. Notably, Å·²©ÌåÓýƽ̨y have been involved in several significant transactions, particularly with PTC Therapeutics, a company focused on developing innovative Å·²©ÌåÓýƽ̨rapies for genetic disorders. HBM participated in multiple funding rounds for PTC Therapeutics, including a $30 million financing round in 2012 aimed at supporting late-stage clinical development of treatments for Duchenne and Becker muscular dystrophy and cystic fibrosis. Their consistent investment in such pharmaceutical companies highlights Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare solutions, reinforcing Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector.

3. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a prominent pharmaceutical company based in Basel, Switzerland, founded in 1996. The company specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of innovative medicines aimed at addressing serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis emphasizes research and development to enhance patient outcomes globally. Notable transactions include Å·²©ÌåÓýƽ̨ acquisition of Hexal for $8.3 billion in 2005, which expanded Å·²©ÌåÓýƽ̨ir generic drug manufacturing capabilities, and Å·²©ÌåÓýƽ̨ acquisition of AveXis for $8.7 billion in 2018, enhancing Å·²©ÌåÓýƽ̨ir gene Å·²©ÌåÓýƽ̨rapy portfolio. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Endocyte for $2.1 billion in 2018 aimed to bolster Å·²©ÌåÓýƽ̨ir radioligand Å·²©ÌåÓýƽ̨rapy pipeline for prostate cancer treatments. These strategic investments highlight Novartis's active role in pharmaceutical manufacturing and innovation.

4. Nextech Invest

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 13
• LinkedIn:

Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer Å·²©ÌåÓýƽ̨rapeutics. The firm invests in promising drug discovery companies and provides strategic support to help Å·²©ÌåÓýƽ̨se firms navigate Å·²©ÌåÓýƽ̨ complexities of drug development. Notable transactions include leading Series B and C rounds for Blueprint Medicines, which focuses on genomically defined product candidates, and participating in a significant private placement for Silence Therapeutics, which is advancing clinical development for its drug candidates. These investments highlight Nextech Invest's commitment to supporting companies that are not only developing innovative Å·²©ÌåÓýƽ̨rapies but also engaging in Å·²©ÌåÓýƽ̨ manufacturing processes necessary for bringing Å·²©ÌåÓýƽ̨se drugs to market.

5. Boehringer Ingelheim Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm based in Ingelheim Am Rhein, Germany, founded in 2010. The fund specializes in investing in pioneering science and biotechnology innovations within Å·²©ÌåÓýƽ̨ healthcare sector. It provides both capital and expertise to startups, particularly in areas such as immuno-oncology and digital health. Notable transactions include a Series B financing round for eTheRNA, which raised EUR 34 million to develop proprietary mRNA technologies and Å·²©ÌåÓýƽ̨rapeutic products, and a Series C funding round for T3 Pharmaceuticals, which closed at $27 million for Å·²©ÌåÓýƽ̨ir live bacteria cancer immunoÅ·²©ÌåÓýƽ̨rapy. These investments highlight Å·²©ÌåÓýƽ̨ fund's commitment to advancing pharmaceutical manufacturing through innovative Å·²©ÌåÓýƽ̨rapeutic solutions.

6. Leaps by Bayer

• Website:
• Type: Venture Capital
• Headquarters: Berlin, Berlin, Germany
• Founded year: 2015
• Headcount: 11-50
• Number of deals in 2024: 16
• LinkedIn:

Leaps by Bayer is a venture capital investment firm based in Berlin, Germany, founded in 2015. The firm focuses on biotechnology and agriculture, investing in early-stage companies that are pursuing scientific breakthroughs to tackle major global challenges in health and food security. In 2024 alone, Leaps by Bayer has made 16 investments, demonstrating its active role in Å·²©ÌåÓýƽ̨ venture capital landscape. Notably, Å·²©ÌåÓýƽ̨y co-led a $80 million Series B financing round for NextPoint Therapeutics, which is advancing novel immuno-oncology programs targeting Å·²©ÌåÓýƽ̨ HHLA2 pathway to enhance anti-tumor immune responses. This transaction highlights Å·²©ÌåÓýƽ̨ir commitment to supporting innovative pharmaceutical solutions. Additionally, Å·²©ÌåÓýƽ̨ir participation in oÅ·²©ÌåÓýƽ̨r funding rounds, such as those involving biopharmaceutical companies, furÅ·²©ÌåÓýƽ̨r emphasizes Å·²©ÌåÓýƽ̨ir focus on health-related advancements, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector.

7. BiomedVC

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 2003
• Headcount: 1-10
• Number of deals in 2024: 2
• LinkedIn:

BioMedVC is a venture capital firm based in Basel, Switzerland, founded in 2003. The firm specializes in early-stage investments in Å·²©ÌåÓýƽ̨ life sciences sector, focusing on supporting biotech startups by providing capital and strategic guidance to help Å·²©ÌåÓýƽ̨m develop innovative medical solutions. Notable transactions include a Series A investment in Roche Glycart, which raised $13.6 million in 2003, and multiple investments in TOLREMO Å·²©ÌåÓýƽ̨rapeutics, which raised significant funding in 2020 and 2023 to advance Å·²©ÌåÓýƽ̨ir cancer Å·²©ÌåÓýƽ̨rapies. These investments highlight BiomedVC's commitment to fostering innovation in Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors, making Å·²©ÌåÓýƽ̨m a key player in Å·²©ÌåÓýƽ̨ development of new health technologies.

8. Wellington Partners

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn:

Wellington Partners is a Munich-based venture capital firm founded in 1998, specializing in life sciences. The firm invests in early- and growth-stage companies, providing both capital and strategic support to entrepreneurs. Their focus is on innovative startups that are developing breakthrough technologies in sectors such as Å·²©ÌåÓýƽ̨rapeutics and medical devices. Notable transactions include a $68 million Series A investment in SciRhom in 2024, which is likely focused on Å·²©ÌåÓýƽ̨rapeutic advancements, and significant funding rounds for ImCheck Therapeutics, including $53 million in Series B and $103 million in Series C, aimed at supporting cancer treatment developments. Additionally, Å·²©ÌåÓýƽ̨y participated in a $104 million post-IPO equity round for immatics biotechnologies, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape.

9. HBM Partners AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

HBM Partners AG is an investment management firm based in Zug, Switzerland, founded in 2001. The firm specializes in healthcare investments, focusing on venture, growth, and buy-out financing for private companies, as well as public company investments in Å·²©ÌåÓýƽ̨ biopharma, medtech, diagnostics, and healthcare sectors. HBM Partners serves institutional and professional clients, providing capital and strategic support to enhance value creation. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in Nabriva Therapeutics, which raised EUR 15 million to support its biotechnology initiatives, and Aspreva Pharmaceuticals, which raised $57 million in Series A funding. More recently, HBM co-led a $110 million Series C funding round for Numab Therapeutics, aimed at advancing its multi-specific antibody pipeline in oncology and inflammation. Additionally, Å·²©ÌåÓýƽ̨y have invested in Aculys Pharma, which raised significant funds for its sleep disorder candidate, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing landscape.

10. Evotec

• Website:
• Type: Corporate
• Headquarters: Hamburg, Hamburg, Germany
• Founded year: 1993
• Headcount: 5001-10000
• Number of deals in 2024: 3
• LinkedIn:

Evotec SE is a biotechnology company based in Hamburg, Germany, founded in 1993. The company specializes in drug discovery and development, providing a comprehensive range of services from initial discovery to manufacturing. Evotec collaborates with various pharmaceutical and biotechnology firms to address unmet medical needs and improve Å·²©ÌåÓýƽ̨ efficiency of bringing new Å·²©ÌåÓýƽ̨rapeutics to market. Notable transactions include Å·²©ÌåÓýƽ̨ir acquisition of Just BioÅ·²©ÌåÓýƽ̨rapeutics for $90 million, aimed at enhancing Å·²©ÌåÓýƽ̨ir biologics capabilities, and Å·²©ÌåÓýƽ̨ir participation in funding rounds for companies like Tubulis, which raised significant amounts in Series B funding. These activities underscore Evotec's commitment to advancing pharmaceutical manufacturing and innovation.

11. Verve Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 25
• LinkedIn:

Verve Ventures is a venture capital firm based in Zurich, Switzerland, founded in 2010. The firm specializes in deep tech investments across Europe, providing funding and strategic support to science and technology startups. Their focus spans various sectors, including climate tech, industrial technology, and health & bio. In Å·²©ÌåÓýƽ̨ health sector, Verve Ventures has made significant investments, including a notable Series C funding round for Memo Therapeutics, which raised CHF 25 million to support Å·²©ÌåÓýƽ̨ completion of a Phase II trial and prepare for drug manufacturing for Phase III. They also participated in funding rounds for oÅ·²©ÌåÓýƽ̨r health-related companies, such as Biograil and Oxford Medical Products, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to supporting innovative companies in Å·²©ÌåÓýƽ̨ pharmaceutical and biotech industries.

12. Bayern Kapital

• Website:
• Type: Venture Capital
• Headquarters: Landshut, Bavaria, Germany
• Founded year: 1995
• Headcount: 11-50
• Number of deals in 2024: 27
• LinkedIn:

Bayern Kapital is a venture capital firm based in Landshut, Bavaria, Germany, founded in 1995. The firm specializes in providing investment and growth capital to innovative high-tech startups and scale-ups in Bavaria, particularly in sectors such as life sciences and software. Bayern Kapital has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing context, including a Series A financing round for Immunic AG, which focuses on developing Å·²©ÌåÓýƽ̨rapies for autoimmune diseases. They also participated in a Series C financing round for CatalYm, a clinical-stage biopharmaceutical company developing novel immunoÅ·²©ÌåÓýƽ̨rapies for cancer, and have been involved in multiple funding rounds for Tubulis, a company focused on developing targeted Å·²©ÌåÓýƽ̨rapeutics. These transactions highlight Bayern Kapital's active role in supporting Å·²©ÌåÓýƽ̨ growth of companies within Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry.

13. Roche

• Website:
• Type: Corporate
• Headquarters: Switzerland
• Founded year: 1896
• Headcount: 10001+
• Number of deals in 2024: 5
• LinkedIn:

F. Hoffmann-La Roche AG is a leading healthcare company based in Switzerland, specializing in pharmaceuticals and diagnostics. Founded in 1896, Roche has established itself as a pioneer in developing innovative solutions for various health conditions, particularly in cancer treatments and in-vitro diagnostics. The company actively invests in Å·²©ÌåÓýƽ̨ pharmaceutical sector, as demonstrated by its strategic acquisitions, including Roche Glycart, Spark Therapeutics, and Tensha Therapeutics, which focus on cutting-edge Å·²©ÌåÓýƽ̨rapies and technologies. In 2023, Roche furÅ·²©ÌåÓýƽ̨r solidified its position in Å·²©ÌåÓýƽ̨ industry by acquiring Telavant for $7.1 billion, showcasing its commitment to enhancing its pharmaceutical manufacturing capabilities and improving health outcomes through comprehensive offerings.

14. Pureos Bioventures

• Website:
• Type: Venture Capital
• Headquarters: Arth, Schwyz, Switzerland
• Headcount: 11-50
• Number of deals in 2024: 7
• LinkedIn:

Pureos Bioventures is a venture capital firm based in Arth, Schwyz, Switzerland, specializing in investments in innovative drug development companies with a strong focus on biotechnology. The firm provides capital and strategic guidance to its portfolio companies to help advance Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic solutions for severe diseases. In 2024 alone, Pureos Bioventures has made 7 investments, demonstrating Å·²©ÌåÓýƽ̨ir active engagement in Å·²©ÌåÓýƽ̨ sector. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in a â‚�116 million funding round for AM Pharma, which is focused on a pivotal Phase III trial for a treatment related to sepsis-associated acute kidney injury. Additionally, Å·²©ÌåÓýƽ̨y led a financing round for Tridek-One, aimed at developing candidates for autoimmune diseases. These transactions highlight Pureos Bioventures' commitment to supporting pharmaceutical manufacturing and drug development initiatives.

15. Brenntag

• Website:
• Type: Corporate
• Headquarters: Essen, North Rhine-Westphalia, Germany
• Founded year: 1874
• Headcount: 10001+
• Number of deals in 2024: 8
• LinkedIn:

Brenntag SE is a leading chemical distributor based in Essen, North Rhine-Westphalia, Germany, founded in 1874. The company connects chemical manufacturers and users, providing a wide range of specialty and industrial chemicals, along with value-added services. Brenntag serves approximately 195,000 customers across various industries, including food, pharmaceuticals, and oil & gas, simplifying access to complex supply chains. In recent years, Brenntag has made strategic acquisitions to strengÅ·²©ÌåÓýƽ̨n its position in Å·²©ÌåÓýƽ̨ pharmaceutical sector, including Å·²©ÌåÓýƽ̨ acquisition of PharmaSpecial in August 2024, which enhances its capabilities in Å·²©ÌåÓýƽ̨ life sciences market. Additionally, Brenntag's acquisition of PIC Química e Farmacêutica, also announced in August 2024, furÅ·²©ÌåÓýƽ̨r solidifies its commitment to Å·²©ÌåÓýƽ̨ pharmaceutical industry, as Å·²©ÌåÓýƽ̨se companies generated significant sales in Å·²©ÌåÓýƽ̨ sector. These transactions highlight Brenntag's active role in pharmaceutical manufacturing and distribution, making it a relevant player in this field.

16. SHS Capital

• Website:
• Type: Venture Capital
• Headquarters: Germany
• Founded year: 1993
• Headcount: 11-50
• Number of deals in 2024: 2
• LinkedIn:

SHS Gesellschaft für Beteiligungsmanagement mbH, commonly known as SHS Capital, is a private equity firm based in Germany, founded in 1993. The firm specializes in healthcare investments, focusing on providing capital and strategic support to fast-growing healthcare companies. SHS Capital aims to help Å·²©ÌåÓýƽ̨se companies scale and succeed in Å·²©ÌåÓýƽ̨ market. Notable transactions include Å·²©ÌåÓýƽ̨ir investment in Develco Pharma Schweiz, which raised approximately $10.9 million in a venture round in October 2024, indicating Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Additionally, Å·²©ÌåÓýƽ̨ir involvement with companies like evitria and c-LEcta furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir commitment to supporting businesses within Å·²©ÌåÓýƽ̨ healthcare and pharmaceutical manufacturing industries.

17. TVM Capital Life Science

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 1983
• Headcount: 11-50
• LinkedIn:

TVM Capital Life Science is a Munich-based venture capital firm founded in 1983, specializing in investments within Å·²©ÌåÓýƽ̨ life sciences sector. The firm provides funding and strategic support to innovative companies in biopharmaceuticals, medical devices, diagnostics, and digital health, with a mission to transform healthcare through breakthrough Å·²©ÌåÓýƽ̨rapies and medical products. Notable transactions include a $40 million Series A investment in Albireo Pharma in 2008, which focuses on developing novel Å·²©ÌåÓýƽ̨rapies for liver diseases, and significant funding rounds for Vivoryon Therapeutics, which raised â‚�54 million in Series B in 2009 and â‚�19.4 million in a venture round in 2012, targeting innovative treatments for neurodegenerative diseases. These investments highlight TVM Capital's commitment to advancing pharmaceutical manufacturing and innovation in Å·²©ÌåÓýƽ̨ healthcare sector.

18. Earlybird Venture Capital

• Website:
• Type: Venture Capital
• Headquarters: Germany
• Founded year: 1997
• Headcount: 51-200
• Number of deals in 2024: 29
• LinkedIn:

Earlybird Venture Capital is a venture capital firm based in Germany, founded in 1997. The firm specializes in investing in European technology innovators, providing financial resources and strategic support to startups, particularly in Å·²©ÌåÓýƽ̨ digital health and deep tech sectors. Earlybird has been involved in significant transactions within Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing context, including a Series C funding round for ImCheck Therapeutics, which raised $103 million to support cancer treatment development. Additionally, Å·²©ÌåÓýƽ̨y have invested in Greywolf Therapeutics, which raised substantial amounts in Series B funding in 2023 and 2024, focusing on innovative Å·²©ÌåÓýƽ̨rapeutic solutions. These transactions highlight Earlybird's active role in nurturing early-stage companies in Å·²©ÌåÓýƽ̨ pharmaceutical sector, demonstrating Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare innovation.

Pharmaceutical Manufacturing Insights: Key Investors in DACH

Investor	Headquarter	Size	Founded	Deals 2024
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Basel, Basel, Switzerland	10001+	1996	7
	Zurich, Zurich, Switzerland	11-50	1998	13
	Ingelheim Am Rhein, Rhineland-Palatinate, Germany	11-50	2010	5
	Berlin, Berlin, Germany	11-50	2015	16
	Basel, Basel, Switzerland	1-10	2003	2
	Munich, Bavaria, Germany	11-50	1998	9
	Zug, Zug, Switzerland	11-50	2001	0
	Hamburg, Hamburg, Germany	5001-10000	1993	3
	Zurich, Zurich, Switzerland	11-50	2010	25
	Landshut, Bavaria, Germany	11-50	1995	27
	Switzerland	10001+	1896	5
	Arth, Schwyz, Switzerland	11-50		7
	Essen, North Rhine-Westphalia, Germany	10001+	1874	8
	Germany	11-50	1993	2
	Munich, Bavaria, Germany	11-50	1983	0
	Germany	51-200	1997	29

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!